Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC (2019)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1016/j.jtho.2019.01.016
- Subjects: NEOPLASIAS PULMONARES; QUIMIOTERAPIA; QUALIDADE DE VIDA; IMUNOHISTOQUÍMICA; ANTINEOPLÁSICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of thoracic oncology
- ISSN: 1556-0864
- Volume/Número/Paginação/Ano: v. 14, n. 5, p. 793-801, 2019
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
BARLESI, Fabrice et al. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, v. 14, n. 5, p. 793-801, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.01.016. Acesso em: 31 mar. 2026. -
APA
Barlesi, F., Garon, E. B., Kim, D. -W., Felip, E., Han, J. -Y., Kim, J. -H., et al. (2019). Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, 14( 5), 793-801. doi:10.1016/j.jtho.2019.01.016 -
NLM
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016 -
Vancouver
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016 - Non-gastrointestinal stromal tumours soft tissue sarcomas: an update
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Epidemiologia do câncer de pulmão
- Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
- Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus
- The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer
- Desenvolvimento de fármacos: pesquisa clínica e medicina de precisão
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Real-World molecular testing and treatment patterns in brazilian patients with newly diagnosed locally advanced or metastatic NSCLC
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
